Potential Therapeutic Targets of B7 Family in Colorectal Cancer

Wang, Changgang; Feng, Haoran; Cheng, Xi; K, Liu; Cai, Dongli; Zhao, Ren

doi:10.3389/fimmu.2020.00681

Cited by 28 publications

(31 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B7-H7 , which has previously been referred to as B7-H5 , is known as the human endogenous retro virus–H long repeat-associating 2 ( HHLA2 ) [ 99 , 100 ]. Its receptors can be found on various immune cells, e.g., monocytes, T cells, B cells, and dendritic cells.…”

Section: Discussionmentioning

confidence: 99%

The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review

Ahangar

Hemmat

Khalaj‐Kondori

et al. 2021

IJMS

View full text Add to dashboard Cite

The members of the B7 family, as immune checkpoint molecules, can substantially regulate immune responses. Since microRNAs (miRs) can regulate gene expression post-transcriptionally, we conducted a scoping review to summarize and discuss the regulatory cross-talk between miRs and new B7 family immune checkpoint molecules, i.e., B7-H3, B7-H4, B7-H5, butyrophilin like 2 (BTNL2), B7-H6, B7-H7, and immunoglobulin like domain containing receptor 2 (ILDR2). The current study was performed using a six-stage methodology structure and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. PubMed, Embase, Scopus, Cochrane, ProQuest, and Google Scholar were systematically searched to obtain the relevant records to 5 November 2020. Two authors independently reviewed the obtained records and extracted the desired data. After quantitative and qualitative analyses, we used bioinformatics approaches to extend our knowledge about the regulatory cross-talk between miRs and the abovementioned B7 family members. Twenty-seven articles were identified that fulfilled the inclusion criteria. Studies with different designs reported gene–miR regulatory axes in various cancer and non-cancer diseases. The regulatory cross-talk between the aforementioned B7 family molecules and miRs might provide valuable insights into the pathogenesis of various human diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review

Ahangar

Hemmat

Khalaj‐Kondori

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The B7 family molecules regulate T-cell activation, tolerance and autoimmunity by providing crucial positive (costimulatory) or negative (coinhibitory) secondary signals[ 8 ]. Ten members of this family have been reported so far: CD80 (B7-1), CD86 (B7-2), programmed death-ligand (PD-L)1 (B7-H1), PD-L2 (B7-DC or CD273), ICOSL (B7-H2), CD276 (B7-H3), B7S1 (B7-H4, B7x, or Vtcn1), VISTA (B7-H5, GI24, or PD-1H), B7-H6 and B7-H7 (HHLA2)[ 11 ].…”

Section: B7-h3mentioning

confidence: 99%

“…B7-H3 (CD276), a type I transmembrane glycoprotein encoded by chromosome 15, was identified as a homolog of the B7 family in 2001. This molecule shares 20%–27% amino acid identity with other B7 family members and has two isoforms in humans: 2Ig-B7-H3 and 4Ig-B7-H3[ 11 - 13 ]. Although the expression of B7-H3 mRNA is ubiquitously found in multiple normal tissues, B7-H3 protein is relatively rarely expressed in physiological conditions, probably due to posttranscriptional regulatory mechanisms[ 11 , 14 ].…”

Section: B7-h3mentioning

confidence: 99%

“…This molecule shares 20%–27% amino acid identity with other B7 family members and has two isoforms in humans: 2Ig-B7-H3 and 4Ig-B7-H3[ 11 - 13 ]. Although the expression of B7-H3 mRNA is ubiquitously found in multiple normal tissues, B7-H3 protein is relatively rarely expressed in physiological conditions, probably due to posttranscriptional regulatory mechanisms[ 11 , 14 ]. B7-H3 is found to be expressed on endothelial cells, nonimmune resting fibroblasts, amniotic fluid stem cells and osteoblasts.…”

Section: B7-h3mentioning

confidence: 99%

See 1 more Smart Citation

B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors

Rasic¹,

Jovanović-Tucović²,

Jeremic³

et al. 2021

WJGO

View full text Add to dashboard Cite

The most common digestive system (DS) cancers, including tumors of the gastrointestinal tract (GIT) such as colorectal cancer (CRC), gastric cancer (GC) and esophageal cancer (EC) as well as tumors of DS accessory organs such as pancreatic and liver cancer, are responsible for more than one-third of all cancer-related deaths worldwide, despite the progress that has been achieved in anticancer therapy. Due to these limitations in treatment strategies, oncological research has taken outstanding steps towards a better understanding of cancer cell biological complexity and heterogeneity. These studies led to new molecular target-driven therapeutic approaches. Different in vivo and in vitro studies have revealed significant expression of B7 homologue 3 (B7-H3) among the most common cancers of the GIT, including CRC, GC, and EC, whereas B7-H3 expression in normal healthy tissue of these organs was shown to be absent or minimal. This molecule is able to influence the biological behavior of GIT tumors through the various immunological and nonimmunological molecular mechanisms, and some of them are shown to be the result of B7-H3-related induction of signal transduction pathways, such as Janus kinase 2/signal transducer and activator of transcription 3, phosphatidylinositol 3-kinase/protein kinase B, extracellular signal-regulated kinase, and nuclear factor-κB. B7-H3 exerts an important role in progression, metastasis and resistance to anticancer therapy in these tumors. In addition, the results of many studies suggest that B7-H3 stimulates immune evasion in GIT tumors by suppressing antitumor immune response. Accordingly, it was observed that experimental depletion or inhibition of B7-H3 in gastrointestinal cancers improved antitumor immune response, impaired tumor progression, invasion, angiogenesis, and metastasis and decreased resistance to anticancer therapy. Finally, the high expression of B7-H3 in most common cancers of the GIT was shown to be associated with poor prognosis. In this review, we summarize the established data from different GIT cancer-related studies and suggest that the B7-H3 molecule could be a promising prognostic biomarker and therapeutic target for anticancer immunotherapy in these tumors.

show abstract

“…B7 family members have received attention because they are expressed on T cells in cases of immune evasion and tumorigenesis. To date, ten B7 family molecules have been identified: B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), B7-DC (CD273 or PD-L2), B7-H2 (ICOSLG, CD275), B7-H3 (CD276), B7-H4 (B7S1, B7x or VTCN1), B7-H5 (VISTA, GI24, or PD-1H), B7-H6 (NCR3LG1) and B7-H7 (HHLA2) ( 3 ). Using the TCGA and GTEx databases, we investigated the mRNA expression levels of B7 family proteins in lymphoma.…”

Section: Introductionmentioning

confidence: 99%

B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?

et al. 2021

View full text Add to dashboard Cite

T cells play a vital role in the immune responses against tumors. Costimulatory or coinhibitory molecules regulate T cell activation. Immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have shown remarkable benefits in patients with various tumor, but few patients have displayed significant immune responses against tumors after PD-1/PD-L1 immunotherapy and many have been completely unresponsive. Thus, researchers must explore novel immune checkpoints that trigger durable antitumor responses and improve clinical outcomes. In this regard, other B7 family checkpoint molecules have been identified, namely PD-L2, B7-H2, B7-H3, B7-H4 and B7-H6. The aim of the present article was to address the expression, clinical significance and roles of B7 family molecules in lymphoma, as well as in T and NK cell-mediated tumor immunity. B7 family checkpoints may offer novel and immunotherapeutic strategies for patients with lymphoma.

show abstract

Potential Therapeutic Targets of B7 Family in Colorectal Cancer

Cited by 28 publications

References 70 publications

The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review

The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review

B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors

B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?

Contact Info

Product

Resources

About